Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | STK16 | O75716 | 1/20 | 0.38 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298554 | 0.99 | BTK (0.45) | BTKCYP3A4PAK1CYP2C19BRD4 | |
| SCHEMBL299062 | 0.89 | MAP2K4 (0.44) | BTKCYP3A4PAK1NEK2AAK1 | |
| SCHEMBL298125 | 0.89 | PAK1 (0.48) | BTKCYP3A4PAK1CYP2C19BRD4 | |
| SCHEMBL297235 | 0.88 | AAK1 (0.44) | BTKPAK1BRD4NEK2AAK1 | |
| SCHEMBL298501 | 0.88 | MAP2K4 (0.46) | BTKCYP3A4PAK1BRD4NEK2 | |
| SCHEMBL298747 | 0.88 | PAK1 (0.47) | BTKCYP3A4PAK1CYP2C19BRD4 | |
| SCHEMBL299341 | 0.87 | AAK1 (0.43) | BTKPAK1NEK2AAK1ADRB3 | |
| SCHEMBL297098 | 0.85 | PAK1 (0.49) | BTKCYP3A4PAK1CYP2C19NEK2 | |
| SCHEMBL298856 | 0.84 | CYP2C19 (0.49) | CYP3A4PAK1CYP2C19NEK2MAP2K4 | |
| SCHEMBL299488 | 0.84 | PAK1 (0.54) | PAK1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BTK 515/4885CYP3A4 3611/4885PAK1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.